Substituted N-(2-oxoethyl) benzamide derivative as well as preparation method and application thereof
By developing and synthesizing a substituted N-(2-oxoethyl)benzamide derivative, combining ULK1 protein to inhibit autophagy, the problem of limited effect of existing ULK1 inhibitors is solved, and the tumor cells is achieved Effective inhibition and immune escape solution, especially in the treatment of liver tumors.
Patent Information
- Application Number
- CN202411043190.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-31
AI Technical Summary
The existing ULK1 inhibitors have limited effects in anti-tumor treatment and are difficult to effectively inhibit the growth and immune escape of tumor cells.
Develop a substituted N-(2-oxoethyl)benzamide derivative, which inhibits autophagy by binding to ULK1 protein, thereby exerting anti-tumor activity. The preparation method includes the use of HATU and DIEA and other compounds, and the Pharmaceutically acceptable carrier or excipient binding.
This compound showed significant anti-tumor activity, could effectively inhibit the ULK1 protein, and could potentially become a new anti-tumor drug, especially in the treatment of liver tumors.
Smart Images

Figure CN118955391A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a substituted N-(2-oxoethyl)benzamide derivative and a preparation method and application thereof. Background Art
[0002] Autophagy is a defense and stress regulation mechanism. Cells eliminate, degrade and digest damaged, denatured, aged and dysfunctional cells, organelles, denatured proteins and nucleic acids and other biomacromolecules through autophagy and lysosomes, providing the necessary raw materials for cell reconstruction, regeneration and repair, and achieving cell recycling and reuse. Many important studies have found that autophagy plays a pivotal role in tissue homeostasis and human diseases such as cancer, neurodegeneration, infection, immunity and aging.
[0003] Autophagy is a "double-edged sword" for tumor cells. On the one hand, autophagy can prompt tumor cells to initiate programmed cell death, and induced autophagy can promote apoptosis of tumor cells. On the other hand, tumor cells can quickly adapt to microenvironments that are not conducive to their growth through autophagy, such as starvation, hypoxia, infection, and immune surveillance. Tumor cells maximize their utilization efficiency of nutrients through autophagy, and can also escape immune surveillance through autophagy. In addition, autophagy can also make tumor cells resistant to radiotherapy, chemotherapy, and immunotherapy. Autophagy provides a protective umbrella for the occurrence and development of tumors. Therefore, autophagy has become a potential therapeutic target for tumor treatment, and ULK1 has also become a potential therapeutic target for tumor treatment.
[0004] ULK1 is a serine / threonine protein kinase and one of the important human cell autophagy-related genes, located at q24.3 of human chromosome 12. Studies have shown that tumors are closely related to cell autophagy, and small molecule inhibitors of ULK1 have potential uses in tumor treatment. The relevant reports are as follows: SBI-0206965 can inhibit the phosphorylation of ULK1 at sites on VPS34 and BECN1, and can selectively unify the endogenous ULK1 kinase activity in vivo. The inhibitor has a significant therapeutic effect on lung cancer. CN108066336A discloses a pharmaceutical preparation using melinamide as an active ingredient or the only active ingredient for the preparation of ULK1 inhibitors, cell autophagy inhibitors, and blocking tumor immune escape and / or enhancing cellular immunity. Studies have shown that melinamide can significantly inhibit the expression level of ULK1 protein in tumor cells. The use of small molecule ULK1 inhibitors can effectively inhibit autophagy, induce apoptosis, and inhibit tumor cell growth [Si-Tu Xue, et al., Autophagy 2020, 16(10): 1823-1837 Huiyu R, et al., J. Med. Chem. 2020, 63: 14609-14625].
[0005] In view of the connection between ULK1 inhibitors and anti-tumor activity, the applicant's research team initiated research on the structure of compounds that inhibit ULK1 protein activity. In the process of extensive screening of compounds that bind to ULK1 protein, certain results have been achieved, and a patent with authorization announcement number CN 112358435B has been obtained. This application was also generated under the same research background. Summary of the invention
[0006] One of the objects of the present invention is to provide a substituted N-(2-oxoethyl)benzamide derivative.
[0007] Another object of the present invention is to provide a method for synthesizing the substituted N-(2-oxoethyl)benzamide derivatives.
[0008] Another object of the present invention is to provide a pharmaceutical composition comprising the above-mentioned substituted N-(2-oxoethyl)benzamide derivatives and, optionally, one or more pharmaceutically acceptable carriers or excipients.
[0009] Another object of the present invention is to provide the use of the substituted N-(2-oxoethyl)benzamide derivatives in the anti-tumor field.
[0010] Definition of terms
[0011] The terms used in the description of the present invention herein are only for describing specific embodiments and are not intended to limit the present invention. The nomenclature used herein and the laboratory operations in the organic chemistry, medicinal chemistry, and biology described herein are well known and commonly used in the art. Unless otherwise mentioned, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this art belongs.
[0012] As used in the description of the embodiments of the present invention and the appended claims, the singular forms "a", "an", "the", and "its" refer to both the singular and the plural, unless the context clearly dictates otherwise. For example, a compound includes one or more than one compound.
[0013] As used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items.
[0014] As used herein, the term "disease" refers to any change in the state of the body or some organ that interrupts or interferes with the performance of its functions and / or causes symptoms.
[0015] As used herein, the term "treatment" is intended to alleviate or eliminate the disease state or condition being targeted. If the subject receives a therapeutic amount of a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, according to the methods described herein, and one or more signs and symptoms of the subject show an observable and / or detectable decrease or improvement, the subject is successfully "treated". It should also be understood that the treatment of the disease state or condition includes not only complete treatment, but also not achieving complete treatment, but achieving some biological or medically relevant results.
[0016] As used herein, the term "subject" may refer to a patient or other animal receiving the composition of the present invention to treat, prevent, alleviate and / or alleviate the disease or condition described in the present invention, and in the present invention, particularly refers to humans and mammals.
[0017] "Halo" and "halogen" refer to an atom selected from fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br) and iodine (iodo, -I).
[0018] The term "C1-C8 alkyl" refers to an optionally substituted straight or branched chain saturated hydrocarbon containing 1 to 8 carbon atoms. It includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, etc.
[0019] "C3-C8 cycloalkyl" refers to a saturated cyclic aliphatic monocyclic ring system having 3 to 8 carbon ring atoms as described herein, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl and cyclooctyl.
[0020] Technical Theme 1
[0021] A substituted N-(2-oxoethyl)benzamide derivative, the structure of which is shown in Formula I:
[0022]
[0023] in,
[0024] R1 represents a C1-C8 straight or branched alkyl group, a C3-C8 cycloalkyl group, a C2-C6 ester group, an R4 substituted or unsubstituted benzyl ring, an R4 substituted or unsubstituted naphthalene ring;
[0025] R4 is one or more, independently representing halogen, C1-C6 straight chain or branched alkyl, 1-3 halogenated C1-C5 alkyl, wherein the halogen represents F, Cl, Br, I;
[0026] R2 is selected from a C1-C6 straight or branched alkoxy group, a C2-C6 ester group;
[0027] R3 is selected from
[0028] As a further improvement of the present invention, the R1 represents a C1-C6 straight or branched alkyl group, a C3-C6 cycloalkyl group, a C1-C5 straight or branched alkoxycarbonyl group, an R4 substituted or unsubstituted benzyl ring, an R4 substituted or unsubstituted benzyl group,
[0029] R4 is one or more, independently representing F, C1-C6 straight chain or branched alkyl, 1-3 halogenated C1-C5 alkyl;
[0030] R2 is selected from
[0031] R3 is selected from
[0032] As a further improvement of the present invention, the C1-C6 straight or branched alkyl group is selected from CH3, CH2CH3, CH(CH3)2, (CH2)2CH3, (CH2)3CH3, CH2CH(CH3)2, C(CH3)3, CH(CH3)CH2CH3, (CH2)4CH3, CH(CH3)(CH2)2CH3, CH(CH2CH3)2, CH2C(CH3)3, CH2CH(CH3)CH2CH3, C(CH3)2CH2CH3, CH(CH3)CH(CH3)2,
[0033] (CH2)2CH(CH3)2, CH2CH(CH2CH3)2, CH2(CH2)4CH3, CH2CH(CH3)CH2CH2CH3, CH2CH2CH(CH3)CH2CH3, CH2CH2CH2CH(CH3)2;
[0034] The C3-C6 cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexane;
[0035] The 1-3 halogenated C1-C5 alkyl group is selected from CF3, CH2CF3, (CH2)2CF3, (CH2)3CF3, (CH2)4CF3;
[0036] The C2-C6 ester group is selected from C(O)OCH3, C(O)OCH2CH3, C(O)OCH(CH3)2, C(O)O(CH2)2CH3, C(O)O(CH2)3CH3, C(O)OCH2CH(CH3)2, C( O)OC(CH3)3, C(O)OCH(CH3)CH2CH3, C(O)O(CH2)4CH3, C(O)OCH(CH3)(CH2)2CH3, C(O)OCH(CH2CH3)2, C(O)OCH2C(CH 2)3. C(O)OCH2CH(CH3)CH2CH3, C(O)OC(CH3)2CH2CH3, C(O)OCH(CH3)CH(CH3)2, C(O)O(CH2)2CH(CH3)2, CH2C(O)OCH 3. CH2C(O)OC2H5, CH2C(O)O(CH2)2CH3, CH2C(O)OCH(CH3)2, (CH2)2C(O)OCH3, (CH2)2C(O)OC2H5 or (CH2)3C(O)OCH3.
[0037] As a further improvement of the present invention, the R1 represents the following structure:
[0038]
[0039] As a further improvement of the present invention, the compound is selected from the following:
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046] Technical Theme 2
[0047] A method for preparing a substituted N-(2-oxoethyl)benzamide derivative as described in the first technical theme, wherein the synthetic route is as follows:
[0048]
[0049]
[0050] Wherein, R1, R2, and R3 are consistent with those described in claim 1;
[0051] Step S1 is to activate substrate a, HATU and DIEA in 1.4-dioxane under stirring at room temperature for 15-30 minutes, then add 5-phenylhydantoin to the system and stir at room temperature for 15-20 hours;
[0052] Step S2 is to stir the substrate b obtained in step S1 with trifluoroacetic acid in dichloromethane at room temperature for 3-5 hours;
[0053] Step S3 is to activate 3,5-disubstituted benzoic acid, HATU and DIEA in 1,4-dioxane under stirring at room temperature for 15-25 minutes, then add reaction substrate c to the system and stir at room temperature for 15-20 hours;
[0054] 3,5-Disubstituted benzoic acid
[0055] As a further improvement of the present invention, the dosage relationship of the preparation method is as follows:
[0056] Among them, the molar ratio of substrate a to HATU, DIEA, and 5-phenylhydantoin in S1 is 1:0.8-1.2:2.5-3.5:1.0-1.5;
[0057] The molar ratio of 3,5-disubstituted benzoic acid to HATU, DIEA, and substrate c in S3 is 1.0-1.5:1.0-1.5:3.0-4.0:1.
[0058] Technical Theme 3
[0059] A pharmaceutical composition comprising a substituted N-(2-oxoethyl)benzamide derivative having a structure shown in Formula I described in Technical Subject 1, and optionally, one or more pharmaceutically acceptable carriers or excipients.
[0060] As used herein, "pharmaceutical composition" contains a therapeutically effective amount of the substituted N-(2-oxoethyl)benzamide derivative of formula I and one or more pharmaceutically acceptable carriers, prepared in the form of tablets, capsules, granules, powders, suspensions, emulsions, powders, solutions, gels, syrups, pills, tinctures, wines, decoctions, lozenges, mixtures, suppositories, injections, inhalants or sprays. The pharmaceutical composition preferably contains 0.1% to 99.5% by weight of the substituted N-(2-oxoethyl)benzamide derivative of the present invention as an active ingredient, and more preferably contains 0.5% to 99.5% by weight of the active ingredient.
[0061] As used herein, "pharmaceutically acceptable carriers or excipients" include: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, colorants, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants and buffers. Those skilled in the art will understand that certain pharmaceutically acceptable excipients can be used in more than one function and in alternative functions, depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation. For example, when used for oral administration, oral preparations such as tablets, capsules, granules and pills can be prepared, containing fillers (e.g., sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives such as corn starch, potato starch, dextrin and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium; gum arabic; dextran; silicate derivatives such as magnesium aluminum metasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; sulfate derivatives such as calcium sulfate, etc.), binders (e.g., gelatin, polyvinyl pyrrolidone and polyethylene glycol), disintegrants (e.g., cellulose derivatives such as sodium carboxymethyl cellulose, polyvinyl pyrrolidone), lubricants (e.g., talc, calcium stearate, magnesium stearate, spermaceti, boric acid, sodium benzoate, leucine), stabilizers (methyl parahydroxybenzoate, propyl parahydroxybenzoate, etc.), flavoring agents (e.g., commonly used sweeteners, acidulants and spices, etc.). When used for parenteral administration, an injection can be prepared, including sterile powder for injection and solvent for injection, and the carrier or excipient used includes sterile water, Ringer's solution and isotonic sodium chloride solution, and suitable additives such as antioxidants, buffers and antibacterial agents can also be added according to the properties of the drug. When used for rectal administration, the drug can be prepared into suppositories, etc. When used for pulmonary administration, the drug can be prepared into inhalants or sprays, etc. There are many resources available to those skilled in the art, which describe pharmaceutically acceptable excipients and can be used to select suitable pharmaceutically acceptable excipients, such as books such as "Remington's Pharmaceutical Encyclopedia", "Chinese Pharmaceutical Annals", and "Pharmaceutics".
[0062] The present invention can be administered by any suitable method known in the art, for example, orally, intravenously, intraperitoneally, intramuscularly, topically, transdermally, ocularly, nasally, by inhalation, subcutaneously, intramuscularly, buccally, sublingually, and rectal administration, and the compound as described above can be administered in any amount of 1 μg to 2000 mg / kg of the subject's body weight, for example, 1 μg to 1000 mg / kg body weight / day, 50 μg to 1000 mg / kg body weight / day, 100 μg to 1000 mg / kg body weight / day, 1 to 500 mg / kg body weight / day, 2 to 200 mg / kg body weight / day, and 5 to 100 mg / kg body weight / day. In some embodiments of the present invention, the compound as described above can be administered 4 times a day, 3 times a day, 2 times a day, 1 time a day, 1 time every two days, 1 time a week, or other intervals, and the dosage regimen as described above can be repeated weekly or monthly as appropriate. In the present invention, the dosage of the compound can be adjusted according to factors such as the severity of the patient's or subject's condition, age, weight, gender, administration method, and course of treatment.
[0063] The compounds of the present invention can be used alone, or in combination with one or more other active ingredients for the treatment, prevention, inhibition or improvement of a disease or condition, wherein the combined use of the drugs is safer or more effective than the use of any one drug alone. Such other drugs can be administered simultaneously or sequentially with the compounds of the present invention in the manner and amount commonly used therefor. When the compounds of the present invention are used simultaneously with one or more other drugs, a pharmaceutical composition containing the other drugs and the compounds of the present invention in a unit dosage form is preferred, particularly in combination with a pharmaceutically acceptable carrier. However, combined therapy can also include treatment with the compounds of the present invention and one or more other drugs in different overlapping schedules. It can also be expected that when used in combination with one or more other active ingredients, the compounds of the present invention and other active ingredients can be used in lower doses than when each is used alone. Therefore, in addition to the compounds of the present invention, the pharmaceutical compositions of the present invention also include those compositions containing one or more other active ingredients.
[0064] Technical Theme 4
[0065] According to the application of a substituted N-(2-oxoethyl)benzamide derivative described in technical subject one in the anti-tumor field.
[0066] As a further improvement of the present invention, the tumor is preferably a liver tumor.
[0067] Advantageous Effects of the Invention
[0068] The compound developed by the present invention can bind to UKL1 protein, thereby potentially inhibiting autophagy and exerting anti-tumor activity. The test results show that the series of compounds have anti-tumor activity, which lays a foundation for the development of such compounds into anti-tumor drugs in the future. DETAILED DESCRIPTION
[0069] The present invention is described below in conjunction with specific examples. These examples are not intended to limit the scope of the present invention, but provide guidance for those skilled in the art to prepare and use the compounds, compositions and methods of the present invention. If no specific conditions are specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.
[0070] The parts mentioned in the examples are all molar parts, and the parts in each experimental step are relatively independent and do not affect each other.
[0071] Some of the compounds in this example were synthesized by the following route:
[0072]
[0073] Wherein, R1, R2, and R3 are consistent with those described in claim 1;
[0074] Step S1 is to activate substrate a, HATU and DIEA in 1.4-dioxane under stirring at room temperature for 15-30 minutes, then add 5-phenylhydantoin to the system and stir at room temperature for 15-20 hours;
[0075] Step S2 is to stir the substrate b obtained in step S1 with trifluoroacetic acid in dichloromethane at room temperature for 3-5 hours;
[0076] Step S3 is to activate 3,5-disubstituted benzoic acid, HATU and DIEA in 1,4-dioxane under stirring at room temperature for 15-25 minutes, then add reaction substrate c to the system and stir at room temperature for 15-20 hours;
[0077] 3,5-Disubstituted benzoic acid
[0078] The dosage relationship is as follows:
[0079] Among them, the molar ratio of substrate a to HATU, DIEA, and 5-phenylhydantoin in S1 is 1:0.8-1.2:2.5-3.5:1.0-1.5;
[0080] The molar ratio of 3,5-disubstituted benzoic acid to HATU, DIEA, and substrate c in S3 is 1.0-1.5:1.0-1.5:3.0-4.0:1.
[0081] Example 1
[0082]
[0083] S1: 1 part of Boc-L-cyclopropylglycine, 1 part of HATU and 3 parts of DIEA were placed in 6 ml of 1,4-dioxane and stirred at room temperature for 20 minutes, and then 1.2 parts of 5-phenylhydantoin were added to the system and stirred at room temperature for 18 hours. The solvent in the system was removed by vacuum distillation, extracted with dichloromethane and water, and dried with anhydrous sodium sulfate to obtain a crude product, which was purified by column chromatography using a system of dichloromethane and 10% methanol to obtain a yellow oily substrate b.
[0084] S2: Dissolve substrate b in 6 ml of dichloromethane, add 2 ml of trifluoroacetic acid to the system, stir at room temperature for 4 hours, use reduced pressure distillation, use dichloromethane twice to remove the acid in the system, and spin dry to obtain the crude product substrate c as a white solid.
[0085] S3: 1.2 parts of 3,5-dimethoxybenzoic acid raw material, 1.2 parts of HATU and 3.6 parts of DIEA were stirred and activated at room temperature for 20 minutes in 6 ml of 1,4-dioxane, and then 1 part of substrate c was added to the system and stirred at room temperature for 18 hours. The solvent in the system was removed by vacuum distillation, extracted with dichloromethane and water, and dried over anhydrous sodium sulfate to obtain a crude product. The crude product was purified by column chromatography using a system of dichloromethane and 10% methanol to obtain 2 different R3 final products. The final products were all white solids, and the yield of the final product of the structure of Example 1 was 37%.
[0086] 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.18(d,J=7.3Hz,1H),7.40–7.27(m,5H),7.05(d,J=2.4Hz,2H),6.63 (t,J=2.3Hz,1H),5.98(s,1H),4.64(dd,J=7.2,6.3Hz,1H),3.81(s,5H),1.98(p,J=6.0Hz,1H),0.54–0.44(m,4H).
[0087] Example 2
[0088]
[0089] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclobutylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 2 with a yield of 43%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.13(d,J=7.9Hz,1H),7.40–7.27(m,6H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H), 5.98(s,1H),4.72(dd,J=7.9,7.0Hz,1H),3.81(s,5H),2.40–2.31(m,1H),1.80–1.72(m,2H),1.76–1.68(m,3H),1.71–1.64(m,1H).
[0090] Example 3
[0091]
[0092] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclopentylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 3 with a yield of 47%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.02(d,J=8.6Hz,1H),7.40–7.31(m,4H),7.34–7.27(m,1H),7.05(d,J=2.4Hz,2H),6.63(t, J=2.3Hz,1H),5.98(s,1H),4.68(dd,J=8.6,7.7Hz,1H),3.81(s,4H),2.37(dp,J=7.6,4.8Hz,1H),1.73–1.63(m,2H),1.63–1.47(m,4H).
[0093] Example 4
[0094]
[0095] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-cyclohexylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 4 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.02(d,J=8.6Hz,1H),7.40–7.27(m,5H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz, 1H),5.98(s,1H),4.67(dd,J=8.7,8.0Hz,1H),3.81(s,4H),2.23(dp,J=7.9,6.0Hz,1H),1.70–1.59(m,2H),1.56–1.25(m,9H).
[0096] Example 5
[0097]
[0098] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-alanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 5 with a yield of 42%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.95(d,J=8.4Hz,1H),7.40–7.31(m,4H),7.34–7.27(m,1H),7.05(d, J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.98(s,1H),4.61(dq,J=8.4,6.2Hz,1H),3.81(s,4H),1.39(d,J=6.3Hz,3H).
[0099] Example 6
[0100]
[0101] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-2-aminobutyric acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 6 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.80(d,J=9.2Hz,1H),7.40–7.34(m,2H),7.37–7.31(m,2H),7.34–7.27(m,1H),7.05(d,J=2. 4Hz,2H),6.63(t,J=2.3Hz,1H),5.92(s,1H),4.50(dt,J=9.0,5.3Hz,1H),3.81(s,4H),1.90(pd,J=7.7,5.5Hz,2H),0.96(t,J=7.4Hz,3H).
[0102] Example 7
[0103]
[0104] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonylnorvaline and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 7 with a yield of 42%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.91(d,J=8.4Hz,1H),7.40–7.27(m,5H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5 .92(s,1H),4.46(dt,J=8.6,6.2Hz,1H),3.81(s,5H),1.90–1.82(m,1H),1.82–1.72(m,1H),1.44–1.34(m,2H),0.94(t,J=7.3Hz,3H).
[0105] Example 8
[0106]
[0107] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonyl D-norleucine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 8 with a yield of 38%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.21(d,J=8.8Hz,1H),7.37(dd,J=8.6,2.2Hz,2H),7.37–7.31(m,2H),7.34–7.27(m,1H),7.05(d,J=2. 4Hz,2H),6.63(t,J=2.3Hz,1H),5.92(s,1H),4.48(dt,J=8.8,6.2Hz,1H), 3.81(s,4H),1.96–1.76(m,2H),1.39–1.22(m,4H),0.90(t,J=7.1Hz,3H).
[0108] Example 9
[0109]
[0110] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-valine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 9 with a yield of 48%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.91(d,J=9.2Hz,1H),7.40–7.27(m,6H),7.05(d,J=2.4Hz,2H),6.63(t,J=2. 3Hz,1H),5.98(s,1H),4.53(dd,J=9.3,6.8Hz,1H),3.81(s,5H),2.06(dt,J=13.9,6.9Hz,1H),0.91(dd,J=7.0,0.9Hz,6H).
[0111] Example 10
[0112]
[0113] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-leucine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 10 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.99(d,J=8.4Hz,1H),7.40–7.27(m,5H),7.05(d,J=2.4Hz,2H),6.63(t, J=2.3Hz,1H),5.92(s,1H),4.66–4.58(m,1H),3.81(s,5H),1.81–1.72(m,1H),1.72–1.61(m,2H),0.91–0.84(m,6H).
[0114] Embodiment 11
[0115]
[0116] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butyloxycarbonyl)amino-4-methylacetic acid and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 11 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.95(d,J=8.8Hz,1H),7.40–7.27(m,6H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.92 (s,1H),4.60(dt,J=8.8,7.2Hz,1H),3.81(s,5H),1.76(dd,J=8.6,7.2Hz,2H),1.68–1.56(m,1H),1.33–1.22(m,2H),0.95–0.84(m,6H).
[0117] Example 12
[0118]
[0119] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-4-ethylhexanoic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 12 with a yield of 47%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.22(d,J=9.0Hz,1H),7.40–7.27(m,5H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5 .92(s,1H),4.61(dt,J=9.2,7.3Hz,1H),3.81(s,5H),1.89–1.78(m,2H),1.74–1.62(m,1H),1.41–1.26(m,4H),0.86(t,J=6.7Hz,6H).
[0120] Example 13
[0121]
[0122] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-3-ethoxy-3-pyruvic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 13 with a yield of 38%. 1 H NMR (500MHz, Chloroform-d): δ9.52(s,1H),8.53(d,J=9.3Hz,1H),7.40–7.27(m,5H),7.05(d,J=2.4Hz,2H),6.6 3(t,J=2.3Hz,1H),6.00(s,1H),5.45(d,J=9.3Hz,1H),4.19(q,J=6.4Hz,2H),3.81(s,5H),1.25(t,J=6.4Hz,3H).
[0123] Embodiment 14
[0124]
[0125] The preparation method is the same as that of Example 1, except that compound a uses N-(tert-butyloxycarbonyl)-L-2-phenylglycine, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 14 with a yield of 47%. 1H NMR (500MHz, Chloroform-d): δ9.48 (s, 1H), 8.30 (d, J = 8.6Hz, 1H), 7.48–7.40 (m, 2H), 7.40–7.26 ( m,8H),7.10(s,1H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.72(dt,J=8.6,1.0Hz,1H),3.81(s,4H).
[0126] Embodiment 15
[0127]
[0128] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butyloxycarbonyl)amino)-2-(p-tolyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 15 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.30(d,J=8.6Hz,1H),7.40–7.34(m,2H),7.37–7.31(m,2H),7.34–7.27(m,1H),7. 31–7.22(m,2H),7.14–7.08(m,2H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),3.81(s,4H),2.34(s,2H).
[0129] Example 16
[0130]
[0131] The preparation method is the same as that of Example 1, except that compound a uses N-Boc-RS-4-fluorophenylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 16 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.30(d,J=8.6Hz,1H),7.42–7.27(m,8H),7.10(d,J=2.4Hz ,2H),7.09–7.02(m,2H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),3.81(s,5H).
[0132] Embodiment 17
[0133]
[0134] The preparation method is the same as that of Example 1, except that compound a uses 2-{[(tert-butoxy)carbonyl]amino}-2-(3-methylphenyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 17 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.19(d,J=8.6Hz,1H),7.40–7.27(m,6H),7.26–7.19(m,2H),7.11(dt,J=2.0,0 .9Hz,1H),7.10(s,1H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.68(dt,J=8.6,1.0Hz,1H),3.81(s,4H),2.34(d,J=1.3Hz,1H).
[0135] Embodiment 18
[0136]
[0137] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butyloxycarbonyl)amino)-2-(3,5-dimethylphenyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 18 with a yield of 47%. 1 H NMR (500MHz, Chloroform-d): δ9.48 (s, 1H), 8.23 (d, J = 8.6Hz, 1H), 7.40–7.34 (m, 2H), 7.37–7.27 (m, 3H), 7.14–7.0 8(m,4H),6.83(td,J=2.4,0.8Hz,1H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.66(dt,J=8.6,1.0Hz,1H),3.81(s,5H).
[0138] Embodiment 19
[0139]
[0140] The preparation method is the same as that of Example 1, except that compound a uses N-tert-butyloxycarbonyl-2-(3-trifluoromethyl-phenyl)-DL-glycine, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 19 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.48 (s, 1H), 8.30 (d, J = 8.6Hz, 1H), 7.65–7.60 (m, 2H), 7.42–7.27 ( m,8H),7.10(s,1H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),3.81(s,5H).
[0141] Embodiment 20
[0142]
[0143] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 20 with a yield of 46%. 1 HNMR (500MHz, Chloroform-d): δ9.48(s,1H),8.19(d,J=8.6Hz,1H),7.72–7.67(m,1H),7.58–7.52(m,1H),7.55–7.45(m,2 H),7.40–7.27(m,5H),7.10(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.72(dt,J=8.6,0.9Hz,1H),3.81(s,4H).
[0144] Embodiment 21
[0145]
[0146] The preparation method is the same as that in Example 1, except that compound a uses 2-(Boc-amino)-2-(2-naphthyl)acetic acid and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 21 with a yield of 47%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.19(d,J=8.6Hz,1H),7.82(d,J=8.5Hz,1H),7.80–7.73(m,3H),7.51(td,J=8.0,1.3Hz,1H ),7.51–7.42(m,2H),7.40–7.27(m,5H),7.10(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.96(s,1H),5.70(d,J=8.6Hz,1H),3.81(s,4H).
[0147] Embodiment 22
[0148]
[0149] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-phenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 22 with a yield of 36%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.27(d,J=9.0Hz,1H),7.40–7.18(m,11H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1 H),5.92(s,1H),4.73(dt,J=9.0,6.9Hz,1H),3.81(s,5H),3.17(ddt,J=14.0,6.8,1.0Hz,1H),3.08(ddt,J=13.9,6.8,0.9Hz,1H).
[0150] Embodiment 23
[0151]
[0152] The preparation method is the same as that of Example 1, except that compound a uses Boc-L-4-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 23 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.51 (s, 1H), 8.27 (d, J = 9.0Hz, 1H), 7.40–7.3 1(m,4H),7.34–7.27(m,1H),7.12–7.08(m,2H),7.08–7.03(m,4H),6.63(t,J =2.3Hz,1H),5.92(s,1H),4.73(dt,J=9.0,6.9Hz,1H),3.81(s,4H),3.15(dd t,J=13.9,6.8,0.9Hz,1H),3.08(ddt,J=14.0,6.8,0.9Hz,1H),2.34(s,2H).
[0153] Embodiment 24
[0154]
[0155] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 24 with a yield of 47%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.27(d,J=9.0Hz,1H),7.40–7.27(m,5H),7.12(dd,J=8.2,7.4Hz,1H),7.07–7.00( m,4H),6.94(p,J=1.5Hz,1H),6.63(t,J=2.3Hz,1H),5.92(s,1H),4.72(dt,J=8.8,6.8Hz,1H),3.81(s,4H),3.14–2.99(m,2H).
[0156] Embodiment 25
[0157]
[0158] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-trifluoromethylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 25 with a yield of 42%. 1 H NMR (500MHz, Chloroform-d): δ9.51 (s, 1H), 8.27 (d, J = 9.0Hz, 1H), 7.50 (ddd, J = 12 .4,2.2,1.2Hz,2H),7.49–7.41(m,1H),7.40–7.27(m,5H),7.17–7.10(m,1H),7.05( d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.92(s,1H),4.72(dt,J=8.8,6.8Hz,1H),3 .81(s,4H),3.16(ddt,J=13.7,6.8,0.9Hz,1H),3.08(ddt,J=13.7,6.8,1.0Hz,1H).
[0159] Embodiment 26
[0160]
[0161] The preparation method is the same as that of Example 1, except that compound a uses Boc-L-cyclopropylglycine and 3,5-diisopropoxybenzoic acid as 3,5-disubstituted benzoic acid to obtain compound 26 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.18(d,J=7.3Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H) ,5.98(s,1H),4.73–4.61(m,3H),1.98(p,J=6.0Hz,1H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H),0.54–0.44(m,4H).
[0162] Embodiment 27
[0163]
[0164] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-cyclobutylglycine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 27 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.13(d,J=7.9Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.98(s,1H),4.7 2(dd,J=7.9,6.9Hz,1H),4.67(dq,J=11.4,5.7Hz,2H),2.40–2.31(m,1H),1.80–1.64(m,5H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0165] Embodiment 28
[0166]
[0167] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-cyclopentylglycine and 3,5-diisopropoxybenzoic acid as 3,5-disubstituted benzoic acid to obtain compound 28 with a yield of 46%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.02(d,J=8.6Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.98(s,1H),4.73–4 .62(m,3H),2.37(dp,J=7.6,4.8Hz,1H),1.73–1.63(m,2H),1.63–1.55( m,4H),1.57–1.47(m,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0168] Embodiment 29
[0169]
[0170] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclohexylglycine and 3,5-diisopropoxybenzoic acid as 3,5-disubstituted benzoic acid to obtain compound 29 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.02(d,J=8.6Hz,1H),7.40–7.31(m,4H),7.34–7.27(m,1H),7.14(s,1H),6.62(t,J=2.3Hz,1H) ,5.98(s,1H),4.73–4.62(m,3H),2.23(dp,J=7.9,6.0Hz,1H),1.70–1 .59(m,2H),1.56–1.45(m,3H),1.48–1.36(m,1H),1.40–1.25(m,16H).
[0171] Embodiment 30
[0172]
[0173] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-alanine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 30 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.95(d,J=8.4Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.9 8(s,1H),4.68(dq,J=11.4,5.7Hz,2H),4.61(dq,J=8.4,6.2Hz,1H),1.39(d,J=6.4Hz,3H),1.34(s,3H),1.30(d,J=5.7Hz,6H).
[0174] Embodiment 31
[0175]
[0176] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-2-aminobutyric acid and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 31 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.80(d,J=9.2Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.92(s,1H),4.6 8(hept,J=5.7Hz,2H),4.50(dt,J=9.0,5.3Hz,1H),1.97–1.83(m,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H),0.96(t,J=7.4Hz,3H).
[0177] Embodiment 32
[0178]
[0179] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonylnorvaline and 3,5-diisopropoxybenzoic acid as 3,5-disubstituted benzoic acid to obtain compound 32 with a yield of 43%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.91(d,J=8.4Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.92(s,1H),4.68(hept,J =5.7Hz,2H),4.46(dt,J=8.6,6.2Hz,1H),1.90–1.72(m,2H),1.44–1.35(m ,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H),0.94(t,J=7.3Hz,3H).
[0180] Embodiment 33
[0181]
[0182] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonyl D-norleucine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 33 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.21(d,J=8.8Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.9 2(s,1H),4.68(hept,J=5.7Hz,2H),4.48(dt,J=8.8,6.2Hz,1H),1.96–1.76(m,2H),1.39–1.22(m,16H),0.90(t,J=7.1Hz,3H).
[0183] Embodiment 34
[0184]
[0185] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-valine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 34 with a yield of 46%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.91(d,J=9.2Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.98(s,1H),4.68(hept, J=5.7Hz,2H),4.53(dd,J=9.3,6.8Hz,1H),2.06(dt,J=13.9,6.9Hz,1H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H),0.91(dd,J=7.0,0.9Hz,6H).
[0186] Embodiment 35
[0187]
[0188] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-leucine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 35 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),7.99(d,J=8.4Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.92(s,1H),4.68( hept,J=5.7Hz,2H),4.66–4.58(m,1H),1.81–1.72(m,1H),1.72–1.61(m,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H),0.91–0.84(m,6H).
[0189] Embodiment 36
[0190]
[0191] The preparation method is the same as that in Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-4-methylacetic acid and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 36 with a yield of 43%. 1H NMR (500MHz, Chloroform-d): δ9.13(s,1H),7.96(d,J=8.6Hz,1H),7.15(d,J=2.4Hz,2H),6.62(t ,J=2.3Hz,1H),6.27(ddq,J=9.0,2.0,1.0Hz,1H),6.17–6.07(m,2H),5.51(tt,J=1.8,1.1Hz,1H) ,4.68(hept,J=5.7Hz,2H),4.61(dt,J=8.8,7.1Hz,1H),2.18–2.07(m,2H),2.04–1.96(m,2H),1. 79–1.72(m,2H),1.69–1.56(m,1H),1.35(d,J=5.7Hz,6H),1.32–1.21(m,8H),0.95–0.84(m,5H).
[0192] Embodiment 37
[0193]
[0194] The preparation method is the same as that in Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-4-ethylhexanoic acid and 3,5-diisopropoxybenzoic acid as 3,5-disubstituted benzoic acid to obtain compound 37 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.22(d,J=9.0Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.92( s,1H),4.73–4.57(m,3H),1.89–1.78(m,2H),1.74–1.62(m,1H),1.41–1.30(m,8H),1.30(d,J=5.7Hz,6H),0.86(t,J=6.7Hz,5H).
[0195] Embodiment 38
[0196]
[0197] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-3-ethoxy-3-pyruvic acid, and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 38 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.52(s,1H),8.53(d,J=9.3Hz,1H),7.40–7.27(m,5H),7.14(s,1H),6.62(t,J=2.3Hz,1H),6.00(s,1H),5. 45(d,J=9.3Hz,1H), 4.68(hept,J=5.7Hz,2H), 4.19(q,J=6.4Hz,2H), 1.35(d,J=5.7Hz,6H), 1.30(d,J=5.7Hz,6H), 1.25(t,J=6.4Hz,3H).
[0198] Embodiment 39
[0199]
[0200] The preparation method is the same as that in Example 1, except that compound a uses N-(tert-butyloxycarbonyl)-L-2-phenylglycine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 39 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.30(d,J=8.6Hz,1H),7.48–7.40(m,2H),7.40–7.25(m,8H),7.18(s,1H),6.62(t, J=2.3Hz,1H),5.96(s,1H),5.72(dt,J=8.6,1.0Hz,1H),4.68(hept,J=5.7Hz,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0201] Embodiment 40
[0202]
[0203] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butoxycarbonyl)amino)-2-(p-tolyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 40 with a yield of 42%. 1H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.30(d,J=8.6Hz,1H),7.40–7.27(m,5H),7.27–7.22(m,2H),7.17(d,J=2.2Hz,2H),7.14–7.08(m ,2H),6.62(t,J=2.3Hz,1H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),4.68(hept,J=5.7Hz,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0204] Embodiment 41
[0205]
[0206] The preparation method is the same as that in Example 1, except that compound a uses N-Boc-RS-4-fluorophenylglycine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 41 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.30(d,J=8.6Hz,1H),7.42–7.27(m,8H),7.17(d,J=2.2Hz,2H),7.10–7.02(m,2H) ,6.62(t,J=2.3Hz,1H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),4.68(hept,J=5.7Hz,2H),1.34(s,3H),1.30(d,J=5.7Hz,6H).
[0207] Embodiment 42
[0208]
[0209] The preparation method is the same as that of Example 1, except that compound a uses 2-{[(tert-butoxy)carbonyl]amino}-2-(3-methylphenyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 42 with a yield of 46%. 1H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.19(d,J=8.6Hz,1H),7.40–7.27(m,5H),7.26–7.15(m,3H),7.13–7.07(m,1H),6.62(t,J=2.3Hz ,1H),5.96(s,1H),5.68(dt,J=8.6,1.0Hz,1H),4.68(hept,J=5.7Hz,2H),2.34(d,J=1.3Hz,1H),1.35(d,J=5.7Hz,5H),1.30(d,J=5.7Hz,5H).
[0210] Embodiment 43
[0211]
[0212] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butyloxycarbonyl)amino)-2-(3,5-dimethylphenyl)acetic acid and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 43 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.23(d,J=8.6Hz,1H),7.40–7.27(m,6H),7.18(s,1H),7.11(dd,J=2.3,1.0Hz,2H),6.83(td,J=2.4,0 .8Hz,1H),6.62(t,J=2.3Hz,1H),5.96(s,1H),5.66(dt,J=8.6,1.0Hz,1H),4.68(hept,J=5.7Hz,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0213] Embodiment 44
[0214]
[0215] The preparation method is the same as that of Example 1, except that compound a uses N-tert-butyloxycarbonyl-2-(3-trifluoromethyl-phenyl)-DL-glycine, and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 44 with a yield of 43%. 1H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.30(d,J=8.6Hz,1H),7.65–7.60(m,2H),7.42–7.27(m,8H),7.17(s,1H),6.62(t, J=2.3Hz,1H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),4.68(hept,J=5.7Hz,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0216] Embodiment 45
[0217]
[0218] The preparation method is the same as that of Example 1, compound a is replaced by 2-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)acetic acid, and 3,5-disubstituted benzoic acid is replaced by 3,5-diisopropoxybenzoic acid to obtain compound 45 with a yield of 43%. 1 HNMR (500MHz, Chloroform-d): δ9.48(s,1H),8.19(d,J=8.6Hz,1H),7.72–7.67(m,1H),7.58–7.52(m,1H),7.55–7.45(m,2H),7.40–7.27(m,5H),7. 17(d,J=2.2Hz,2H),6.62(t,J=2.3Hz,1H),5.96(s,1H),5.72(dt,J=8.6, 0.9Hz, 1H), 4.68 (hept, J = 5.7Hz, 2H), 1.34 (s, 3H), 1.30 (d, J = 5.7Hz, 6H).
[0219] Embodiment 46
[0220]
[0221] The preparation method is the same as that of Example 1, except that compound a uses 2-(Boc-amino)-2-(2-naphthyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 46 with a yield of 46%. 1H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.19(d,J=8.6Hz,1H),7.82(d,J=8.5Hz,1H),7.80–7.73(m,3H),7.55–7.42(m,3H),7.40–7.27(m,5H ),7.17(d,J=2.2Hz,2H),6.62(t,J=2.3Hz,1H),5.96(s,1H),5.70(d,J=8.6Hz,1H),4.68(hept,J=5.7Hz,2H),1.34(s,3H),1.30(d,J=5.7Hz,6H).
[0222] Embodiment 47
[0223]
[0224] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-phenylalanine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 47 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.51 (s, 1H), 8.27 (d, J = 9.0Hz, 1H), 7.40–7.18 (m,11H),7.14(s,1H),6.62(t,J=2.3Hz,1H),5.92(s,1H),4.73(dt,J=9.0,6. 9Hz, 1H), 4.67 (dq, J=11.4, 5.7Hz, 2H), 3.17 (ddt, J=14.0, 6.8, 1.0Hz, 1H), 3. 08(ddt,J=13.9,6.8,0.9Hz,1H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0225] Embodiment 48
[0226]
[0227] The preparation method is the same as that of Example 1, except that compound a uses Boc-L-4-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 48 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.27(d,J=9.0Hz,1H),7.40–7.27(m,5H),7.14(s,1H),7.12–7.03(m,4H),6.62(t ,J=2.3Hz,1H),5.92(s,1H),4.77–4.62(m,3H),3.19–3.04(m,2H),2.34(s,2H),1.35(d,J=5.7Hz,5H),1.30(d,J=5.7Hz,5H).
[0228] Embodiment 49
[0229]
[0230] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 49 with a yield of 42%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.27(d,J=9.0Hz,1H),7.40–7.27(m,5H),7.14(s,1H),7.12(dd,J=8.2,7.4Hz,1H),7.03(ddt,J=7.6,2.1,1 .2Hz,2H),6.94(p,J=1.3Hz,1H),6.62(t,J=2.3Hz,1H),5.92(s,1H),4.76–4 .62(m,3H),3.14–2.99(m,2H),1.35(d,J=5.7Hz,6H),1.30(d,J=5.7Hz,6H).
[0231] Embodiment 50
[0232]
[0233] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-trifluoromethylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-diisopropoxybenzoic acid to obtain compound 50 with a yield of 43%. 1H NMR (500MHz, Chloroform-d): δ9.51 (s, 1H), 8.27 (d, J = 9.0Hz, 1H), 7.50 (ddd, J = 12.4 ,2.2,1.2Hz,2H),7.49–7.41(m,1H),7.40–7.27(m,5H),7.17–7.10(m,3H),6.62(t,J= 2.3Hz,1H),5.92(s,1H),4.76–4.68(m,1H),4.71–4.62(m,2H),3.16(ddt,J=13.7,6. 8,0.9Hz,1H),3.08(ddt,J=13.7,6.8,1.0Hz,1H),1.34(s,3H),1.30(d,J=5.7Hz,6H).
[0234] Embodiment 51
[0235]
[0236] The preparation method is the same as that of Example 1, except that compound a uses Boc-L-cyclopropylglycine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 51 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.20(d,J=7.1Hz,1H),7 .40–7.27(m,5H),5.98(s,1H),4.64(dd,J=7.2,6.3Hz,1H),3.89(s,5H),1.98(p,J=6.0Hz,1H),0.54–0.44(m,4H).
[0237] Embodiment 52
[0238]
[0239] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclobutylglycine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 52 with a yield of 44%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.16(d,J=7.9Hz,1H),7.40–7.2 7(m,6H),5.98(s,1H),4.72(dd,J=7.9,7.0Hz,1H),3.89(s,5H),2.40–2.31(m,1H),1.80–1.68(m,5H),1.71–1.64(m,1H).
[0240] Embodiment 53
[0241]
[0242] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclobutylglycine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 53 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.06(d,J=8.8Hz,1H),7.40–7.27(m,5H),5.98 (s,1H),4.68(dd,J=8.6,7.7Hz,1H),3.89(s,4H),2.37(dp,J=7.6,4.8Hz,1H),1.73–1.63(m,2H),1.63–1.55(m,4H),1.57–1.47(m,2H).
[0243] Embodiment 54
[0244]
[0245] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclohexylglycine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 54 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.06(d,J=8.8Hz,1H),7.40–7.27(m, 5H),5.98(s,1H),4.67(dd,J=8.7,8.0Hz,1H),3.89(s,4H),2.23(dp,J=7.9,6.0Hz,1H),1.70–1.59(m,2H),1.56–1.25(m,9H).
[0246] Embodiment 55
[0247]
[0248] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-alanine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 55 with a yield of 47%. 1 H NMR (500MHz, Chloroform-d): δ8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.10(d,J=8.4Hz,1H),7.38–7.30(m,2H),7.30–7.23(m,4H),5.27(t d,J=3.3,0.8Hz,1H),4.62(dq,J=8.4,6.3Hz,1H),3.89(s,4H),3.51(dt, J=12.5,3.4Hz,1H),3.27(dt,J=12.5,3.4Hz,1H),1.39(d,J=6.4Hz,3H).
[0249] Embodiment 56
[0250]
[0251] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-2-aminobutyric acid and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 56 with a yield of 43%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),7.91(d,J=9.2Hz,1H),7.40– 7.27(m,5H),5.92(s,1H),4.50(dt,J=9.0,5.3Hz,1H),3.89(s,4H),1.90(pd,J=7.7,5.5Hz,2H),0.96(t,J=7.4Hz,3H).
[0252] Embodiment 57
[0253]
[0254] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonylnorvaline and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 57 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.06(d,J=8.4Hz,1H),7.40–7.27(m,5H),5.92(s,1H ),4.46(dt,J=8.6,6.2Hz,1H),3.89(s,5H),1.91–1.82(m,1H),1.82–1. 72(m,1H),1.44–1.38(m,1H),1.40–1.34(m,1H),0.94(t,J=7.3Hz,3H).
[0255] Embodiment 58
[0256]
[0257] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonyl D-norleucine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 58 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.34(d,J=8.8Hz,1H),7.37(dd,J=8.6,2.2Hz,2H),7.37– 7.31(m,2H),7.34–7.27(m,1H),5.92(s,1H),4.48(dt,J=8.8,6.2Hz,1H), 3.89(s,4H),1.96–1.76(m,2H),1.39–1.22(m,4H),0.90(t,J=7.1Hz,3H).
[0258] Embodiment 59
[0259]
[0260] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-valine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 59 with a yield of 48%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),7.94(d,J=9.3Hz,1H),7.40–7.2 7(m,6H),5.98(s,1H),4.53(dd,J=9.3,6.8Hz,1H),3.89(s,5H),2.06(dt,J=13.9,6.9Hz,1H),0.91(dd,J=7.0,0.9Hz,6H).
[0261] Embodiment 60
[0262]
[0263] The preparation method is the same as that in Example 1, except that compound a uses Boc-DL-leucine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 60 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.13(d,J=8.4Hz,1H),7.38–7.30(m,2H),7.30–7.23(m,4H),5.28(t,J=3.3Hz ,1H),4.61–4.53(m,1H),3.89(s,4H),3.51(dt,J=12.5,3.4Hz,1H),3.27(dt, J=12.5,3.4Hz,1H),1.81–1.72(m,1H),1.72–1.60(m,2H),0.91–0.84(m,6H).
[0264] Embodiment 61
[0265]
[0266] The preparation method is the same as that in Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-4-methylacetic acid and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 61 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.13(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.12 (d,J=8.8Hz,1H),6.27(ddq,J=9.0,2.0,1.0Hz,1H),6.17–6.07(m,2H),5.51(tt,J=1.9,1.1Hz, 1H),4.61(dt,J=8.8,7.1Hz,1H),3.89(s,4H),2.18–2.07(m,2H),2.04–1.94(m,2H),1.79–1.72 (m,2H),1.62(ddddd,J=14.8,10.8,7.4,5.4,1.5Hz,1H),1.33–1.21(m,2H),0.95–0.84(m,5H).
[0267] Embodiment 62
[0268]
[0269] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-4-ethylhexanoic acid and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 62 with a yield of 43%. 1H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.34(d,J=9.0Hz,1H),7.40–7.27(m,6H),5 .92(s,1H),4.61(dt,J=9.2,7.3Hz,1H),3.89(s,5H),1.86–1.79(m,2H),1.73–1.62(m,1H),1.41–1.26(m,4H),0.86(t,J=6.7Hz,6H).
[0270] Embodiment 63
[0271]
[0272] The preparation method is the same as that in Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-3-ethoxy-3-pyruvic acid, and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 63 with a yield of 40%. 1 H NMR (500MHz, Chloroform-d): δ9.52 (s, 1H), 8.69–8.63 (m, 2H), 8.55 (d, J = 2.2Hz, 2H), 7.40–7.27 (m ,5H),6.00(s,1H),5.45(d,J=9.3Hz,1H),4.19(q,J=6.4Hz,2H),3.89(s,5H),1.25(t,J=6.4Hz,3H).
[0273] Embodiment 64
[0274]
[0275] The preparation method is the same as that of Example 1, except that compound a uses N-(tert-butyloxycarbonyl)-L-2-phenylglycine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 64 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.48 (s, 1H), 8.65 (t, J = 2.1Hz, 1H), 8.59 (d, J = 2.2Hz, 2H), 8.36 (d, J = 8. 6Hz,1H),7.48–7.40(m,2H),7.40–7.25(m,8H),5.96(s,1H),5.72(dt,J=8.6,0.9Hz,1H),3.89(s,4H).
[0276] Embodiment 65
[0277]
[0278] The preparation method is the same as that in Example 1, except that compound a uses 2-((tert-butoxycarbonyl)amino)-2-(p-tolyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 65 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.48 (s, 1H), 8.65 (t, J = 2.1Hz, 1H), 8.59 (d, J = 2.2Hz, 2H), 8.36 (d, J = 8. 6Hz,1H),7.40–7.22(m,8H),7.14–7.08(m,2H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),3.89(s,5H).
[0279] Embodiment 66
[0280]
[0281] The preparation method is the same as that in Example 1, except that compound a uses N-Boc-RS-4-fluorophenylglycine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 66 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.48 (s, 1H), 8.65 (t, J = 2.1Hz, 1H), 8.59 (d, J = 2.2Hz, 2H), 8.36 (d, J = 8. 6Hz,1H),7.42–7.27(m,8H),7.10–7.02(m,2H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),3.89(s,5H).
[0282] Embodiment 67
[0283]
[0284] The preparation method is the same as that of Example 1, compound a is replaced by 2-{[(tert-butoxy)carbonyl]amino}-2-(3-methylphenyl)acetic acid, and 3,5-disubstituted benzoic acid is replaced by 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 67 with a yield of 45%. 1HNMR (500MHz, Chloroform-d): δ9.48(s,1H),8.65(t,J=2.1Hz,1H),8.59(d,J=2.2Hz,2H),8.28(d,J=8.6Hz,1H),7.40–7.35(m,2H),7.37–7.32(m ,2H),7.33(dt,J=2.2,1.1Hz,1H),7.34–7.27(m,1H),7.26–7.19(m,2H), 7.13–7.07(m,1H),5.96(s,1H),5.68(dt,J=8.6,1.0Hz,1H),3.89(s,5H).
[0285] Embodiment 68
[0286]
[0287] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butyloxycarbonyl)amino)-2-(3,5-dimethylphenyl)acetic acid and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 68 with a yield of 41%. 1 HNMR (500MHz, Chloroform-d): δ9.48(s,1H),8.65(t,J=2.1Hz,1H),8.59(d,J=2.2Hz,2H),8.26(d,J=8.6Hz,1H),7.40–7.34(m,2H),7.37–7. 31(m,2H),7.34–7.27(m,1H),7.11(dd,J=2.3,1.0Hz,2H),6.83(td,J=2.3,0.8Hz,1H),5.96(s,1H),5.66(dt,J=8.6,1.0Hz,1H),3.89(s,5H).
[0288] Embodiment 69
[0289]
[0290] The preparation method is the same as that of Example 1, except that compound a uses N-tert-butyloxycarbonyl-2-(3-trifluoromethyl-phenyl)-DL-glycine, and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 69 with a yield of 43%. 1HNMR (500MHz, Chloroform-d): δ9.48(s,1H),8.65(t,J=2.1Hz,1H),8.59(d,J=2.2Hz,2H),8.36(d,J=8 .6Hz,1H),7.65–7.60(m,2H),7.42–7.27(m,8H),5.96(s,1H),5.73(dt,J=8.6,1.0Hz,1H),3.89(s,5H).
[0291] Embodiment 70
[0292]
[0293] The preparation method is the same as that of Example 1, compound a is replaced by 2-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)acetic acid, and 3,5-disubstituted benzoic acid is replaced by 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 70 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.65(t,J=2.1Hz,1H),8.59(d,J=2.2Hz,2H),8.29(d,J=8.6Hz,1H),7.72–7.6 7(m,1H),7.58–7.52(m,1H),7.55–7.45(m,2H),7.40–7.27(m,5H),5.96(s,1H),5.72(dt,J=8.6,1.0Hz,1H),3.89(s,4H).
[0294] Embodiment 71
[0295]
[0296] The preparation method is the same as that of Example 1, except that compound a uses 2-(Boc-amino)-2-(2-naphthyl)acetic acid and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 71 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.48(s,1H),8.65(t,J=2.1Hz,1H),8.59(d,J=2.2Hz,2H),8.28(d,J=8.6Hz,1H),7.82(d,J=8.5Hz,1H), 7.80–7.73(m,3H),7.51(td,J=8.0,1.3Hz,1H),7.51–7.42(m,2H),7.40–7.27(m,5H),5.96(s,1H),5.70(d,J=8.6Hz,1H),3.89(s,4H).
[0297] Embodiment 72
[0298]
[0299] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-phenylalanine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 72 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.38(d,J=9.0Hz,1H),7.40–7.18(m,11 H),5.92(s,1H),4.73(dt,J=9.0,6.9Hz,1H),3.89(s,5H),3.17(ddt,J=14.0,6.8,1.0Hz,1H),3.08(ddt,J=13.9,6.8,0.9Hz,1H).
[0300] Embodiment 73
[0301]
[0302] The preparation method is the same as that of Example 1, except that compound a uses Boc-L-4-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 73 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.3 8(d,J=9.0Hz,1H),7.40–7.34(m,2H),7.37–7.33(m,1H),7.36–7.31(m,1H),7.33–7.27(m,1H) ,7.12–7.08(m,2H),7.06(dt,J=7.8,1.0Hz,2H),5.92(s,1H),4.73(dt,J=9.0,6.9Hz,1H),3.8 9(s,4H),3.15(ddt,J=13.9,6.8,0.9Hz,1H),3.08(ddt,J=14.0,6.8,0.9Hz,1H),2.34(s,2H).
[0303] Embodiment 74
[0304]
[0305] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 74 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2Hz,2H),8.38(d,J=9.0Hz,1H),7.40–7.27(m,5H),7.12(dd,J= 8.2,7.4Hz,1H),7.03(ddq,J=7.5,2.4,1.2Hz,2H),6.96–6.92(m,1H),5 .92(s,1H),4.72(dt,J=8.8,6.8Hz,1H),3.89(s,4H),3.14–2.99(m,2H).
[0306] Embodiment 75
[0307]
[0308] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-trifluoromethylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-di(methoxycarbonyl)benzoic acid to obtain compound 75 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ9.51(s,1H),8.65(t,J=2.1Hz,1H),8.55(d,J=2.2H z,2H),8.38(d,J=9.0Hz,1H),7.50(ddd,J=12.4,2.2,1.2Hz,2H),7.49–7.41(m,1H) ,7.40–7.27(m,5H),7.17–7.10(m,1H),5.92(s,1H),4.72(dt,J=8.8,6.8Hz,1H),3 .89(s,4H),3.16(ddt,J=13.7,6.8,0.9Hz,1H),3.08(ddt,J=13.7,6.8,1.0Hz,1H).
[0309] Embodiment 76
[0310]
[0311] The preparation method is the same as that of Example 1, except that compound a uses Boc-L-cyclopropylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 76 with a yield of 52%. 1H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.15(d,J=7.3Hz,1H),7.44–7.36(m,2H),7.34–7.26(m,3H),7.05(d,J=2.4Hz,2H),6. 63(t,J=2.3Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.63(dd,J=7.4,6.5Hz,1H),3.81(s,5H),1.99(dt,J=12.4,5.9Hz,1H),0.56–0.42(m,4H).
[0312] Embodiment 77
[0313]
[0314] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclobutylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 77 with a yield of 52%. 1 H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.10(d,J=8.2Hz,1H),7.43–7.36(m,2H),7.34–7.26(m,3H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3H z,1H),5.63(dd,J=6.0,0.9Hz,1H),4.71(dd,J=8.1,7.1Hz,1H),3.81(s,4H) ,2.43–2.34(m,1H),1.80–1.72(m,2H),1.75–1.68(m,2H),1.71–1.63(m,1H).
[0315] Embodiment 78
[0316]
[0317] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclopentylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 78 with a yield of 49%. 1H NMR (500MHz, Chloroform-d): δ8.34 (d, J = 6.0 Hz, 1H), 8.05 (d, J = 9.0 Hz, 1H), 7. 43–7.36(m,2H),7.34–7.26(m,3H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H ),5.63(dd,J=6.1,0.9Hz,1H),4.68(dd,J=8.8,7.9Hz,1H),3.81(s,5H),2.40( dp,J=8.1,4.9Hz,1H),1.73–1.63(m,2H),1.63–1.55(m,4H),1.57–1.47(m,2H).
[0318] Embodiment 79
[0319]
[0320] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-cyclohexylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 79 with a yield of 48%. 1 H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.05(d,J=9.0Hz,1H),7.43–7.36(m,2H),7.34–7.26(m,3H),7.05(d,J=2.4Hz,2H),6.63(t,J= 2.3Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.68(dd,J=9.0,8.2Hz,1H),3.81 (s,5H),2.28(dp,J=8.2,6.0Hz,1H),1.70–1.60(m,2H),1.56–1.25(m,9H).
[0321] Embodiment 80
[0322]
[0323] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-alanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 80 with a yield of 50%. 1H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),7.94(d,J=8.6Hz,1H),7.43–7.36(m,2H),7.34–7.27(m,3H),7.05(d,J=2 .4Hz,2H),6.63(t,J=2.3Hz,1H),5.63(dd,J=6.1,0.9Hz,1H),4.59(dq,J=8.6,6.4Hz,1H),3.81(s,5H),1.36(d,J=6.6Hz,3H).
[0324] Embodiment 81
[0325]
[0326] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-2-aminobutyric acid and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 81 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),7.79(d,J=9.3Hz,1H),7.44–7.36(m,2H),7.34–7.27(m,3H),7.05(d,J=2.4Hz,2H),6.6 3(t,J=2.3Hz,1H),5.63(dd,J=6.1,0.9Hz,1H),4.47(dt,J=9.3,5.6Hz,1H),3.81(s,4H),1.94(pd,J=7.3,5.5Hz,2H),0.95(t,J=7.5Hz,3H).
[0327] Embodiment 82
[0328]
[0329] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonylnorvaline and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 82 with a yield of 45%. 1H NMR(500MHz,Chloroform-d): δ8.34(d,J=6.0Hz,1H),7.89(d,J=8.6Hz,1H),7 .44–7.36(m,2H),7.34–7.27(m,3H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz, 1H), 5.63 (dd, J=6.0, 0.9Hz, 1H), 4.50 (dt, J=8.6, 6.4Hz, 1H), 3.81 (s, 5H), 1. 95–1.86(m,1H),1.86–1.76(m,1H),1.44–1.33(m,2H),0.94(t,J=7.3Hz,3H).
[0330] Embodiment 83
[0331]
[0332] The preparation method is the same as that of Example 1, except that compound a uses tert-butyloxycarbonyl D-norleucine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 83 with a yield of 43%. 1 H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.20(d,J=9.0Hz,1H),7.40(ddt,J=6.2,5.4,2.1Hz,2H),7.34–7.26(m,3H),7.05(d,J=2.4Hz,2H), 6.63(t,J=2.3Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.50(dt,J=9.1,6.4Hz,1 H),3.81(s,4H),1.98–1.80(m,2H),1.39–1.21(m,4H),0.90(t,J=7.1Hz,3H).
[0333] Embodiment 84
[0334]
[0335] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-valine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 84 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),7.75(d,J=9.5Hz,1H),7.43–7.36(m,2H),7.34–7.27(m,3H),7.05(d,J=2.4Hz,2H),6.63(t ,J=2.3Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.52(dd,J=9.5,7.0Hz,1H),3.81(s,5H),2.08(dt,J=13.9,7.0Hz,1H),0.91(dd,J=6.9,0.9Hz,6H).
[0336] Embodiment 85
[0337]
[0338] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-leucine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 85 with a yield of 52%. 1 H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.02(d,J=8.6Hz,1H),7.43–7.36(m,2H),7.34–7.27(m,3H),7.05(d,J=2.4Hz,2H),6.63(t,J= 2.3Hz, 1H), 5.63 (dd, J=6.1, 0.9Hz, 1H), 4.63 (dt, J=8.6, 7.2Hz, 1H), 3.81 (s,5H),1.79–1.68(m,2H),1.72–1.62(m,1H),0.88(dd,J=6.4,0.6Hz,6H).
[0339] Embodiment 86
[0340]
[0341] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-4-methylacetic acid and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 86 with a yield of 47%. 1H NMR(500MHz,Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.01(d,J=8.8Hz,1H),7. 43–7.36(m,2H),7.34–7.26(m,3H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H ),5.63(dd,J=6.0,0.9Hz,1H),4.61(dt,J=9.0,7.4Hz,1H),3.81(s,5H),1.77( dd,J=8.7,7.3Hz,2H),1.68–1.56(m,1H),1.33–1.21(m,2H),0.95–0.84(m,6H).
[0342] Embodiment 87
[0343]
[0344] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-4-ethylhexanoic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 87 with a yield of 47%. 1 H NMR(500MHz,Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.19(d,J=9.2Hz,1H),7 .43–7.36(m,2H),7.34–7.27(m,3H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz, 1H),5.63(dd,J=6.1,0.9Hz,1H),4.61(dt,J=9.2,7.5Hz,1H),3.81(s,5H),1. 86–1.77(m,2H),1.73–1.62(m,1H),1.41–1.26(m,4H),0.86(t,J=6.7Hz,6H).
[0345] Embodiment 88
[0346]
[0347] The preparation method is the same as that of Example 1, except that compound a uses 2-(tert-butoxycarbonyl)amino-3-ethoxy-3-pyruvic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 88 with a yield of 45%. 1H NMR (500MHz, Chloroform-d): δ8.65(d,J=9.5Hz,1H),8.46(d,J=6.0Hz,1H),7.43–7.36(m,2H),7.34–7.27(m,3H),7.05(d,J=2.4H z,2H),6.63(t,J=2.3Hz,1H),5.64–5.59(m,1H),5.48(d,J=9.7Hz,1H),4.19(q,J=6.4Hz,2H),3.81(s,4H),1.25(t,J=6.4Hz,3H).
[0348] Embodiment 89
[0349]
[0350] The preparation method is the same as that of Example 1, except that compound a uses N-(tert-butyloxycarbonyl)-L-2-phenylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 89 with a yield of 45%. 1 H NMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,1H),8.39(d,J=8.8Hz,1H),7.47–7.36(m,4H),7.35–7.25(m, 4H),7.10(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.68(dt,J=8.8,1.0Hz,1H),5.65–5.61(m,1H),3.81(s,5H).
[0351] Embodiment 90
[0352]
[0353] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butoxycarbonyl)amino)-2-(p-tolyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 90 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,1H),8.39(d,J=8.8Hz,1H),7.40(ddt,J=6.2,5.4,2.1Hz,2H),7.34–7.23( m,5H),7.14–7.08(m,2H),6.63(t,J=2.3Hz,1H),5.71(dt,J=8.8,1.0Hz,1H),5.66–5.61(m,1H),3.81(s,4H),2.34(s,2H).
[0354] Embodiment 91
[0355]
[0356] The preparation method is the same as that of Example 1, except that compound a uses N-Boc-RS-4-fluorophenylglycine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 91 with a yield of 49%. 1 H NMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,1H),8.39(d,J=8.8Hz,1H),7.44–7.35(m,4H),7.34–7.28(m,3H),7.10 (d,J=2.4Hz,2H),7.09–7.02(m,2H),6.63(t,J=2.3Hz,1H),5.72(dt,J=9.0,1.1Hz,1H),5.66–5.61(m,1H),3.81(s,4H).
[0357] Embodiment 92
[0358]
[0359] The preparation method is the same as that of Example 1, except that compound a uses 2-{[(tert-butoxy)carbonyl]amino}-2-(3-methylphenyl)acetic acid, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 92 with a yield of 47%. 1 H NMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,2H),8.21(d,J=8.8Hz,2H),7.44–7.36(m,4H),7.34(ddd,J=7.8,2.2,1.1Hz,2H),7.34–7.26(m,6H),7.2 6–7.19(m,4H),7.11(dt,J=2.1,1.0Hz,1H),7.10(s,2H),6.63(t,J=2.3Hz,2 H),5.69(dt,J=8.8,1.0Hz,2H),5.66–5.61(m,2H),3.81(s,9H),2.34(s,1H).
[0360] Embodiment 93
[0361]
[0362] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butyloxycarbonyl)amino)-2-(3,5-dimethylphenyl)acetic acid and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 93 with a yield of 46%. 1 H NMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,1H),8.34(d,J=8.8Hz,1H),7.43–7.36(m,2H),7.34–7.27(m,2H),7.14–7. 08(m,4H),6.83(td,J=2.3,0.8Hz,1H),6.63(t,J=2.3Hz,1H),5.72(dt,J=8.8,1.0Hz,1H),5.66–5.61(m,1H),3.81(s,5H).
[0363] Embodiment 94
[0364]
[0365] The preparation method is the same as that of Example 1, except that compound a uses N-tert-butyloxycarbonyl-2-(3-trifluoromethyl-phenyl)-DL-glycine, and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 94 with a yield of 47%. 1 H NMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,1H),8.39(d,J=8.8Hz,1H),7.65–7.60(m,2H),7.44–7.36(m,4H),7.34 –7.27(m,2H),7.10(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.72(dt,J=8.8,0.9Hz,1H),5.66–5.61(m,1H),3.81(s,4H).
[0366] Embodiment 95
[0367]
[0368] The preparation method is the same as that of Example 1, except that compound a uses 2-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)acetic acid and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 95 with a yield of 49%. 1HNMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,1H),8.21(d,J=8.8Hz,1H),7.71(td,J=2.1,0.9Hz,1H),7.58–7.52(m,1H),7.55–7.44(m,2H), 7.44–7.36(m,2H),7.34–7.26(m,3H),7.10(d,J=2.4Hz,2H),6.63(t,J= 2.3Hz,1H),5.70(dt,J=8.9,0.9Hz,1H),5.66–5.61(m,1H),3.81(s,5H).
[0369] Embodiment 96
[0370]
[0371] The preparation method is the same as that of Example 1, except that compound a uses 2-(Boc-amino)-2-(2-naphthyl)acetic acid and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 96 with a yield of 52%. 1 H NMR (500MHz, Chloroform-d): δ8.61(d,J=6.0Hz,1H),8.21(d,J=8.8Hz,1H),7.85–7.73(m,5H),7.51(td,J=8.1,1.5Hz,1H),7.51–7.43(m,2H ),7.43–7.36(m,2H),7.34–7.26(m,3H),7.10(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.70(d,J=8.8Hz,1H),5.66–5.61(m,1H),3.81(s,5H).
[0372] Embodiment 97
[0373]
[0374] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-phenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 97 with a yield of 44%. 1H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.25(d,J=9.2Hz,1H),7.43–7.36(m,2H),7.34–7.18(m,8H),7.05(d,J=2.4Hz,2H),6.63(t,J=2. 3Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.70(dt,J=9.2,7.1Hz,1H),3.81(s, 4H), 3.16(ddt,J=14.1,7.1,1.0Hz,1H), 3.07(ddt,J=14.0,7.1,1.0Hz,1H).
[0375] Embodiment 98
[0376]
[0377] The preparation method is the same as that of Example 1, except that compound a uses Boc-L-4-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 98 with a yield of 49%. 1 H NMR(500MHz,Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.25(d,J=9.2Hz,1H),7.40 (ddt,J=6.2,5.4,2.1Hz,2H),7.34–7.26(m,3H),7.12–7.03(m,6H),6.63(t,J=2.3 Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.70(dt,J=9.2,7.1Hz,1H),3.81(s,4H),3. 18(ddt,J=13.9,7.0,0.9Hz,1H), 3.09(ddt,J=14.1,7.1,1.0Hz,1H), 2.34(s,2H).
[0378] Embodiment 99
[0379]
[0380] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-methylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 99 with a yield of 48%. 1H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.25(d,J=9.2Hz,1H),7.44–7.36 (m,2H),7.34–7.26(m,3H),7.12(dd,J=8.2,7.4Hz,1H),7.07–7.00(m,4H),6.94(p,J=1 .5Hz,1H),6.63(t,J=2.3Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.76(dt,J=9.2,7.0Hz,1 H),3.81(s,5H),3.13(ddt,J=13.7,7.1,1.1Hz,1H),3.05(ddt,J=13.7,7.0,0.9Hz,1H).
[0381] Embodiment 100
[0382]
[0383] The preparation method is the same as that of Example 1, except that compound a uses Boc-DL-3-trifluoromethylphenylalanine and 3,5-disubstituted benzoic acid uses 3,5-dimethoxybenzoic acid to obtain compound 100 with a yield of 49%. 1 H NMR (500MHz, Chloroform-d): δ8.34(d,J=6.0Hz,1H),8.25(d,J=9.2Hz,1H),7.50(ddd,J=12.4,2. 2,1.2Hz,2H),7.49–7.40(m,1H),7.40(ddt,J=6.2,5.4,2.3Hz,2H),7.34–7.26(m,3H),7.17–7.10 (m,1H),7.05(d,J=2.4Hz,2H),6.63(t,J=2.3Hz,1H),5.63(dd,J=6.0,0.9Hz,1H),4.76(dt,J=9.2 ,7.1Hz,1H),3.81(s,4H),3.14(ddt,J=13.7,7.1,1.1Hz,1H),3.07(ddt,J=13.8,7.2,0.9Hz,1H).
[0384] Biological Example 1 Determination of the affinity of the compounds for ULK1
[0385] The binding kinetics between the compound and ULK1 were measured by surface plasmon resonance using a Biacore T200 instrument (GE Healthcare, Pittsburgh, PA, USA). The compounds at specified concentrations (50 μL, 25 μL, 12.5 μL, 6.25 μL, 3.125 μL, 1.56 μL) were passed through the ULK1 protein fixed on the CM5 sensor chip, and the dissociation constant (KD) was calculated using BIAevaluation software. The results are shown in Table 1.
[0386] Table 1
[0387] Compound No. SPR assay to determine the KD value (nM) of the interaction between the compound and ULK1 1 32.65±5.34 6 29.76±7.26 7 35.06±5.86 9 43.38±4.56 26 47.75±3.24 31 34.87±5.62 32 37.32±4.28 34 32.53±4.52 51 35.42±3.23 55 31.98±6.34 56 36.42±3.34 57 37.34±5.45 76 34.58±6.43 84 42.23±6.85 88 45.42±2.34
[0388] Antitumor activity test of the compound in biological example 2 on HepG2 cells
[0389] Cell viability was measured with CCK-8: HepG2 cells were seeded in a 96-well plate at a density of 4000 cells / well. The cells were cultured at 38°C for 24 hours, and then the corresponding 10 μM drugs were added and cultured at 38°C for 48 hours. Subsequently, 10 μL of CCK-8 solution (TargetMol) was added to each well, and the cells were incubated at 38°C in the dark for 2 hours. Finally, the absorbance was measured at 450 nm, and the cell viability was calculated by software. The results are shown in Table 2.
[0390] Table 2
[0391]
[0392]
[0393] Antitumor activity test of the compound in biological example 3 on Hep3b cells
[0394] Cell viability was measured by CCK-8: Hep3b cells were seeded in a 96-well plate at a density of 4000 cells / well. The cells were cultured at 38°C for 24 hours, and then the corresponding 20 μM drugs were added and cultured at 38°C for 48 hours. Subsequently, 10 μL of CCK-8 solution (TargetMol) was added to each well, and the cells were incubated at 38°C in the dark for 2 hours. Finally, the absorbance was measured at 450 nm, and the cell viability was calculated by software. The results are shown in Table 3.
[0395] Table 3
[0396] Compound No. Hep3b cell survival rate at 20μM concentration (%) 1 4.78 6 7.23 7 6.89 9 5.73 26 5.54 30 5.64 31 7.44 32 4.23 34 6.69 38 7.65 47 6.89 51 5.34 55 6.73 56 7.23 57 8.23 64 7.59 73 7.76 74 7.53 76 5.94 80 7.54 81 7.53 84 6.96 85 8.09 88 5.78 91 7.80 92 7.99
[0397] Activity test of the compound in biological example 4 on PLC / PRF / 5 cells
[0398] Cell viability was measured by CCK-8: PLC / PRF / 5 cells were seeded in a 96-well plate at a density of 4000 cells / well. The cells were cultured at 38°C for 24 hours, and then the corresponding 20 μM drug was added and cultured at 38°C for 48 hours. Subsequently, 10 μL CCK-8 solution (TargetMol) was added to each well, and the cells were incubated at 38°C in the dark for 2 hours. Finally, the absorbance was measured at 450 nm, and the cell viability was calculated by the software. The results are shown in Table 4.
[0399] Table 4
[0400]
[0401]
[0402] Biological Example 5 Effects of some compounds on HepG2 cells, Hep3b cells, PLC / PRF / 5 cells IC 50 Determination of
[0403] CCK-8 measurement of compound IC in HepG2 cells 50 :HepG2 cells were seeded in 96-well plates at a density of 4000 cells / well and cultured at 38°C for 24 hours. The drugs to be tested were prepared with DMEM culture medium (Gibco) by half-dilution method to concentrations of 100μL, 50μL, 25μL, 12.5μL, 6.25μL, 3.125μL, 1.56μL, and 0.78μL. The original culture medium in the well plate was aspirated, and 100μL of the drug-containing culture medium of the corresponding concentration was added to each well, and cultured at 38°C for 48 hours. Then 10μL of CCK-8 solution (TargetMol) was added to each well, incubated at 38°C in the dark for 2 hours, and finally the absorbance was measured at 450nm, and the cell IC was calculated by software. 50 , the results are shown in Table 5.
[0404] CCK-8 measurement of IC of compounds in Hep3b cells 50 :Hep3b cells were seeded in 96-well plates at a density of 4000 cells / well and cultured at 38°C for 24 hours. The drugs to be tested were prepared with DMEM (Gibco) medium by half-dilution method to concentrations of 100μL, 50μL, 25μL, 12.5μL, 6.25μL, 3.125μL, 1.56μL, and 0.78μL. The original culture medium in the well plate was aspirated, and 100μL of the drug-containing culture medium of the corresponding concentration was added to each well, and cultured at 38°C for 48 hours. Then 10μL of CCK-8 solution (TargetMol) was added to each well, incubated at 38°C in the dark for 2 hours, and finally the absorbance was measured at 450nm, and the cell IC was calculated by software. 50 , the results are shown in Table 6.
[0405] CCK-8 measurement of IC of compounds in PLC / PRF / 5 cells 50 :PLC / PRF / 5 cells were seeded in 96-well plates at a density of 4000 cells / well and cultured at 38°C for 24 hours. The drugs to be tested were prepared with DMEM medium (Gibco) by half-dilution method to concentrations of 100μL, 50μL, 25μL, 12.5μL, 6.25μL, 3.125μL, 1.56μL, and 0.78μL. The original culture medium in the well plate was aspirated, and 100μL of drug-containing culture medium of the corresponding concentration was added to each well, and cultured at 38°C for 48 hours. 10μL CCK-8 solution (TargetMol) was added to each well, incubated at 38°C in the dark for 2 hours, and finally the absorbance was measured at 450nm, and the cell IC was calculated by software 50 , the results are shown in Table 7.
[0406] Table 5
[0407] Compound No. <![CDATA[HepG2 cell IC 50 (μM)]]> 1 21.53 6 9.60 7 18.43 9 7.76 26 16.85 31 18.35 32 9.34 34 16.22 51 19.65 55 8.54 56 20.42 57 16.23 76 13.63 84 20.53 88 16.05
[0408] Table 6
[0409]
[0410]
[0411] Table 7
[0412] Compound No. <![CDATA[PLC / PRF / 5 cell IC 50 (μM)]]> 1 15.34 6 9.05 7 7.05 9 8.74 26 12.25 31 9.75 32 8.75 34 13.42 44 14.34 51 10.89 55 13.06 56 17.89 57 14.34 76 7.68 84 9.94 88 14.23 95 18.76
[0413] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art may still modify the technical solutions described in the aforementioned embodiments, or make equivalent substitutions for some of the technical features therein; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A substituted N-(2-oxoethyl)benzamide derivative, characterized in that: Its structure is shown in Formula I: in, R1 represents a C1-C8 straight or branched alkyl group, a C3-C8 cycloalkyl group, a C2-C6 ester group, an R4 substituted or unsubstituted benzyl ring, an R4 substituted or unsubstituted naphthalene ring; R4 is a monosubstituted or polysubstituted group, independently representing halogen, C1-C6 straight chain or branched alkyl, 1-3 halogenated C1-C5 alkyl, wherein the halogen represents F, Cl, Br, I; R2 is selected from a C1-C6 straight or branched alkoxy group, a C2-C6 ester group; R3 is selected from 2. A substituted N-(2-oxoethyl)benzamide derivative according to claim 1, characterized in that: The R1 represents a C1-C6 straight or branched alkyl group, a C3-C6 cycloalkyl group, a C1-C5 straight or branched alkoxycarbonyl group, an R4 substituted or unsubstituted benzyl ring, an R4 substituted or unsubstituted benzyl group, R4 is a monosubstituted or polysubstituted group, and can independently represent F, a C1-C6 straight chain or branched alkyl group, or a 1-3 halogenated C1-C5 alkyl group; R2 is selected from R3 is selected from 3. A substituted N-(2-oxoethyl)benzamide derivative according to claim 1, characterized in that: The C1-C6 straight or branched alkyl group is selected from CH3, CH2CH3, CH(CH3)2, (CH2)2CH3, (CH2)3CH3, CH2CH(CH3)2, C(CH3)3, CH(CH3)CH2CH3, (CH2)4CH3, CH(CH3)(CH2)2CH3, CH(CH2CH3)2, CH2C(CH3)3, CH2CH(CH3)CH2CH3, C(CH3)2CH2CH3, CH(CH3)CH(CH3)2, (CH2)2CH(CH3)2, CH2CH(CH2CH3)2, CH2(CH2)4CH3, CH2CH(CH3)CH2CH2CH3, CH2CH2CH(CH3)CH2CH3, CH2CH2CH2CH(CH3)2; The C3-C6 cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexane; The 1-3 halogenated C1-C5 alkyl group is selected from CF3, CH2CF3, (CH2)2CF3, (CH2)3CF3, (CH2)4CF3; The C2-C6 ester group is selected from C(O)OCH3, C(O)OCH2CH3, C(O)OCH(CH3)2, C(O)O(CH2)2CH3, C(O)O(CH2)3CH3, C(O)OCH2CH(CH3)2, C( O)OC(CH3)3, C(O)OCH(CH3)CH2CH3, C(O)O(CH2)4CH3, C(O)OCH(CH3)(CH2)2CH3, C(O)OCH(CH2CH3)2, C(O)OCH2C(CH 2)3. C(O)OCH2CH(CH3)CH2CH3, C(O)OC(CH3)2CH2CH3, C(O)OCH(CH3)CH(CH3)2, C(O)O(CH2)2CH(CH3)2, CH2C(O)OCH 3. CH2C(O)OC2H5, CH2C(O)O(CH2)2CH3, CH2C(O)OCH(CH3)2, (CH2)2C(O)OCH3, (CH2)2C(O)OC2H5 or (CH2)3C(O)OCH3.
4. A substituted N-(2-oxoethyl)benzamide derivative according to claim 1, characterized in that: The R1 represents the following structure:
5. A substituted N-(2-oxoethyl)benzamide derivative according to claim 1, characterized in that: The compound is selected from the following:
6. A method for preparing a substituted N-(2-oxoethyl)benzamide derivative according to any one of claims 1 to 5, characterized in that: It is synthesized by the following steps: S1: S2: S3: Wherein, R1, R2, and R3 are consistent with those described in claim 1; Step S1 is to activate substrate a, HATU and DIEA in 1.4-dioxane under stirring at room temperature for 15-30 minutes, then add 5-phenylhydantoin to the system and stir at room temperature for 15-20 hours; Step S2 is to stir the substrate b obtained in step S1 with trifluoroacetic acid in dichloromethane at room temperature for 3-5 hours; Step S3 is to activate 3,5-disubstituted benzoic acid, HATU and DIEA in 1,4-dioxane under stirring at room temperature for 15-25 minutes, then add reaction substrate c to the system and stir at room temperature for 15-20 hours; 3,5-Disubstituted benzoic acid 7. The method for preparing a substituted N-(2-oxoethyl)benzamide derivative according to claim 6, characterized in that: The dosage relationship is as follows: Among them, the molar ratio of substrate a to HATU, DIEA, and 5-phenylhydantoin in S1 is 1:0.8-1.2:2.5-3.5:1.0-1.5; The molar ratio of 3,5-disubstituted benzoic acid to HATU, DIEA, and substrate c in S3 is 1.0-1.5:1.0-1.5:3.0-4.0:
1.
8. A pharmaceutical composition comprising the substituted N-(2-oxoethyl)benzamide derivative according to any one of claims 1 to 5 and, optionally, one or more pharmaceutically acceptable carriers or excipients.
9. Use of a substituted N-(2-oxoethyl)benzamide derivative according to any one of claims 1 to 5 in the preparation of a drug for inhibiting ULK1.
10. Use of a substituted N-(2-oxoethyl)benzamide derivative according to any one of claims 1 to 5 in the preparation of antitumor drugs.
Citation Information
Patent Citations
Drug use of rocaglamide
CN108066336A
Substituted aryl heterocyclic compound, preparation method, ULK1 inhibition and anti-tumor application
CN112358435A
Cited By
Substituted oxazolo six-membered ring compound and application thereof
CN120058735A
